Navigation Links
Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia
Date:7/4/2012

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options. The findings of this new clinical study, carried out by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, suggest eltrombopag could be a second-line therapeutic option for them.

"Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia," will be published online July 5 in the New England Journal of Medicine.

Aplastic anemia is a rare blood disorder, with about 600 new cases in the U.S. each year. Aplastic anemia results from the destruction of bone marrow stem cells, which mature into red blood cells that carry oxygen, white blood cells that fight infection, and platelets that prevent excess bleeding. Symptoms of the disorder include fatigue, frequent infections, and hemorrhaging. In severe cases unresponsive to treatment, death can occur.

Eleven of 25 participants enrolled in this phase 2 study showed improved production of at least one type of blood cell (red blood cell, white blood cell, or platelet) after 12 weeks of oral eltrombopag therapy. Among the seven volunteers who continued taking the pills long-term (8-32 months), six eventually showed an improvement in all three types of blood cells, and were able to maintain safe blood counts without needing red blood cell or platelet transfusions. Overall the drug was well tolerated, with few side effects.

The research team in the NHLBI Hematology Branch tested eltrombopag because this drug had previously been shown to boost platelet levels in both healthy people and people with reduced platelets due to hepatitis C infection or immune thrombocytopenia, blood disorders that like aplastic anemia result in low platelet counts and increased risk of bleeding.

The encouraging finding in this study was improvement in red blood cell and white blood cell counts in some aplastic anemia patients, suggesting that the drug can stimulate bone marrow stem cells and perhaps have wider utility than initially predicted.


'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related medicine news :

1. Gel Shows Promise as Future Male Contraceptive
2. UT Southwestern study shows treating diabetes early, intensively is best strategy
3. Glucose deprivation activates feedback loop that kills cancer cells, UCLA study shows
4. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
5. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
6. Autism Speaks provides strategies to help a child with autism shows difficult behaviors
7. Study shows stagnating life expectancies in US
8. UW research shows new prognosis tool for deadly brain cancer
9. Stanford study shows opiates side effects rooted in patients genetics
10. Study shows no evidence medical marijuana increases teen drug use
11. State Laws Cut Teen Drinking and Driving, Large Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... (PRWEB) , ... August 24, 2017 , ... ... supplements that help people improve all aspects of their health and wellness, has ... , The step represents a component of Natural Subsistence’s aggressive marketing strategy in ...
(Date:8/24/2017)... ... August 24, 2017 , ... AudioEducator is the country’s top ... coming months, AudioEducator has lined up several training sessions on ICD-10 coding ... experts, these healthcare training conferences are designed to update providers with all the ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... President Business Development and Sector Growth. Mr. Smith joins other recent high-profile hires ... , Mr. Smith’s healthcare career began in 1993, helping physician practices and hospitals ...
(Date:8/23/2017)... ... ... The Stevie® Awards have announced the winners of the Best of the IBA Awards in ... , Nominees in the 2017 IBAs were not able to apply for the Best of ... number of awards won in the IBAs with a Gold Stevie win counting for three ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... MD , has returned home to Indiana, and is now seeing patients at ... board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye disease, medical ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology: